Site icon pharmaceutical daily

Intermittent Claudication, Pipeline Review, H1 2020 – Helixmith Co Ltd, ID Pharma Co Ltd & Novartis AG – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Intermittent Claudication – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Intermittent Claudication – Pipeline Review, H1 2020, provides an overview of the Intermittent Claudication (Cardiovascular) pipeline landscape.

Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs and sores or wounds on the lower limb that heal slowly, poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age and family history.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Intermittent Claudication – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Intermittent Claudication (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Intermittent Claudication (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

Intermittent Claudication (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tpy0jt

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version